Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MDVN [NASD]
Medivation, Inc.
Index- P/E81.44 EPS (ttm)1.41 Insider Own0.20% Shs Outstand77.62M Perf Week5.27%
Market Cap8.91B Forward P/E33.44 EPS next Y3.43 Insider Trans13.95% Shs Float76.31M Perf Month13.49%
Income115.00M PEG- EPS next Q1.28 Inst Own95.00% Short Float4.83% Perf Quarter28.33%
Sales532.40M P/S16.74 EPS this Y-1.80% Inst Trans-0.06% Short Ratio3.07 Perf Half Y57.67%
Book/sh3.23 P/B35.55 EPS next Y28.61% ROA24.30% Target Price112.78 Perf Year81.52%
Cash/sh4.14 P/C27.76 EPS next 5Y- ROE83.40% 52W Range54.37 - 113.61 Perf YTD79.93%
Dividend- P/FCF176.15 EPS past 5Y11.70% ROI-7.90% 52W High1.07% Beta0.66
Dividend %- Quick Ratio4.80 Sales past 5Y85.00% Gross Margin- 52W Low111.20% ATR3.85
Employees468 Current Ratio4.80 Sales Q/Q234.20% Oper. Margin27.50% RSI (14)67.28 Volatility3.42% 3.85%
OptionableYes Debt/Eq0.88 EPS Q/Q633.30% Profit Margin21.60% Rel Volume0.74 Prev Close112.26
ShortableYes LT Debt/Eq0.88 EarningsNov 06 AMC Payout0.00% Avg Volume1.20M Price114.83
Recom1.80 SMA207.17% SMA5013.19% SMA20041.93% Volume890,692 Change2.29%
Sep-18-14Upgrade Canaccord Genuity Hold → Buy $60 → $132
Sep-12-14Reiterated Chardan Capital Markets Buy $100 → $122
Sep-11-14Reiterated Stifel Buy $89 → $112
Aug-08-14Reiterated UBS Buy $85 → $90
Aug-08-14Reiterated Stifel Buy $83 → $89
Aug-08-14Reiterated Brean Capital Buy $100 → $105
May-22-14Initiated Stifel Buy $81
Apr-16-14Initiated Canaccord Genuity Hold $60
Mar-17-14Reiterated Maxim Group Buy $92 → $112
Mar-03-14Reiterated UBS Buy $93 → $85
Feb-28-14Reiterated Maxim Group Buy $84 → $92
Feb-03-14Reiterated Chardan Capital Markets Buy $100
Feb-03-14Downgrade Needham Buy → Hold
Jan-29-14Reiterated Maxim Group Buy $75 → $84
Jan-29-14Reiterated Brean Capital Buy $72 → $100
Jan-29-14Reiterated Aegis Capital Buy $100 → $125
Jan-28-14Initiated CRT Capital Buy $88
Jan-10-14Reiterated Barclays Equal Weight $57 → $62
Nov-13-13Reiterated Maxim Group Buy $71 → $75
Nov-13-13Reiterated Barclays Equal Weight $53 → $57
Nov-25-14 04:10PM  Joseph Lobacki to Become Medivation's Chief Commercial Officer Marketwired
Nov-17-14 04:10PM  Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner Marketwired
Nov-14-14 02:30PM  Street Talk: HOG, LULU, BMRN, MDVN & TRS CNBC
01:04PM  MEDIVATION, INC. Financials EDGAR Online Financials
Nov-10-14 10:38AM  Dendreon files bankruptcy protection CNBC
Nov-08-14 07:07PM  10-Q for Medivation, Inc. Company Spotlight
Nov-07-14 04:28PM  Another lackluster session for major equities Yahoo Finance Blogs +7.45%
03:30PM  Major Upgrades And Downgrades In Friday's Market Action Benzinga
12:53PM  Clarification: Earns-Medivation story AP
12:35PM  Midday movers: Allergan, Freshpet, Transocean & more at CNBC
11:15AM  Medivation Hits High After Q3 Earnings Beat at Investor's Business Daily
11:08AM  Medivation Q3 Earnings, Revenues Lag Estimates Zacks
Nov-06-14 04:18PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Third Quarter Financial Results and Provides Corporate Update Marketwired
08:30AM  Deutsche Banks U.S. Stock Selection Best Buy Ideas at 24/7 Wall St.
07:07AM  Q3 2014 Medivation Inc Earnings Release - After Market Close CCBN
Nov-05-14 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
12:54PM  3 Biotech Stocks for Earnings Beats this Season Zacks
08:00AM  Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline at TheStreet
Nov-04-14 02:50PM  Will Humana (HUM) Miss on Earnings Estimates this Season? Zacks
05:32AM  Geron Corporation (GERN) Looks Strong: Stock Up 25.6% Zacks
Nov-03-14 11:50AM  Seattle Genetics Gains on Narrower-than-Expected Q3 Loss Zacks
05:28AM  Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% Zacks
02:23AM  Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% Zacks
Oct-31-14 03:11AM  Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% Zacks
03:07AM  Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% Zacks
Oct-30-14 11:00PM  Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy Marketwired
Oct-28-14 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
06:27AM  Novavax (NVAX) in Focus: Stock Rises 13% Zacks
Oct-27-14 02:15AM  Verastem (VSTM) Shows Strength: Stock Adds 7% in Session Zacks
Oct-24-14 04:25PM  Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case Zacks
01:00PM  BioMarin Q3 Loss Narrower than Expected, View Raised Zacks
08:55AM  Eli Lilly's Q3 Earnings In-Line but Generics Hit Revenues Zacks
06:47AM  Fate Therapeutics (FATE) Crumbles: Stock Tumbles by 10.6% Zacks
Oct-23-14 05:12PM  Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. for Potential Applications in Oncology Marketwired
04:00PM  Medivation Announces Third Quarter 2014 Financial Results Teleconference on November 6, 2014 Marketwired
03:10PM  Omeros Falls as Enrollment for OMS824 Study is Suspended Zacks
02:30PM  Novartis' Secukinumab Receives Favorable FDA Panel Vote Zacks
11:50AM  Celgene Beats Q3 Earnings Estimates on High Revlimid Sales Zacks
Oct-22-14 12:14PM  Value in biotech: Pro CNBC
07:32AM  Orexigen (OREX) Shows Strength: Stock Gains 11.1% Zacks
06:43AM  Illumina (ILMN) Looks Strong: Stock Gains 9.2% Zacks
Oct-21-14 05:05PM  NewLink-Roche Ink Deal for Oncology Candidate Development Zacks
02:30PM  Will Quest Diagnostics (DGX) Surprise Earnings in Q3? Zacks
Oct-17-14 05:07PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:00PM  Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study Zacks
03:30PM  Gilead's Harvoni Receives Notice of Compliance from Canada Zacks
Oct-15-14 05:48PM  GW Pharmaceuticals Down on Disappointing Mid-Stage Data Zacks
04:20PM  Novavax Begins Mid-Stage Study on RSV Vaccine in Elders Zacks
03:30PM  Alnylam Reveals Positive Data from its Pipeline Candidates Zacks
Oct-14-14 11:54AM  J&J Earnings Beat; Olysio Chatter Hits Gilead at Investor's Business Daily
Oct-13-14 04:50PM  Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx Zacks
04:19PM  Celgene's Otezla Encourages in Plaque Psoriasis at EADV Zacks
03:00PM  Targacept's Nine-Year Association with AstraZeneca to End Zacks
Oct-10-14 04:52PM  AstraZeneca's Benralizumab Encourages in Phase II Study Zacks
04:10PM  XOMA Starts Phase I Study on XOMA 358 for Hyperinsulinism Zacks
03:45PM  Momenta Reveals Necuparanib Data for Pancreatic Cancer Zacks
Oct-09-14 05:44PM  What's the Dollar Value of Online Patient Chatter? at BusinessWeek
03:44PM  Amgen Up on Positive Phase III Data on Psoriasis Biosimilar Zacks
03:30PM  Chimerix Falls as Ebola Patient on Brincidofovir Dies in US Zacks
02:26PM  EY Announces leaders from Medivation, MongoDB, Trulia, and zulily inc. recipients of its 2014 Venture Capital Award of Excellence PR Newswire
Oct-08-14 04:50PM  Emergent BioSolutions Revamps Business to Drive Earnings Zacks
10:20AM  Amgen's Data on Evolocumab Published in The Lancet Zacks
Oct-06-14 01:31PM  Consider Medivation for Your Portfolio at Fox Business
Oct-04-14 12:01AM  [$$] A Poor Quarter for U.S. Equity Funds at Barrons.com
Oct-03-14 04:10PM  MannKind Receives $150 Million Upfront Payment from Sanofi Zacks
Oct-02-14 09:20AM  5 Big-Volume Stocks to Trade for Big Breakouts at TheStreet
12:01AM  Hedge Funds Listen In on Patient Chats for Pharma Bets Bloomberg
Sep-29-14 04:30PM  Agios to Present Data on AG-120 in November, Shares Rises Zacks
Sep-26-14 04:10PM  Alnylam Starts New Study on Cardiac Amyloidosis Patients Zacks
Sep-24-14 05:10PM  Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency Zacks
05:00PM  Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug Zacks
11:42AM  How Will Medivation (MDVN) Stock Be Affected Today by This Analyst Action? at TheStreet
11:42AM  [video]How Will Medivation (MDVN) Stock Be Affected Today by This Analyst Action? at TheStreet
Sep-22-14 07:00PM  Cramer's favorite IPO of 2014: Not Alibaba CNBC
07:00PM  [video] Cramer's favorite IPO of 2014: Not Alibaba at CNBC
05:11PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
04:20PM  Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer Zacks
Sep-18-14 01:55PM  Canaccord Genuity Doubles Price Target for Medivation 24/7 Wall St.
08:53AM  Medivation upgraded by Canaccord Genuity Briefing.com
08:23AM  Analysts' Actions: Kohl's, Medivation, Owens-Illinois, Pier 1, More TheStreet
Sep-15-14 07:05AM  Quarterly Changes to the NASDAQ Q-50 Index GlobeNewswire
Sep-12-14 05:24PM  Your first trade for Monday at CNBC
12:58PM  [video] FMHR Final Trade: MDVN, C, NUE at CNBC
Sep-11-14 05:41PM  Medivation Eyes Blockbuster As Cancer Drug Gets An OK at Investor's Business Daily
05:35PM  Medivation-Astellas' Xtandi's Label Expanded by FDA Zacks
08:32AM  Stifel Raises Medivation Inc Price Target Benzinga
Sep-10-14 06:40PM  U.S. FDA approves expanded use of Medivation prostate cancer drug Reuters
05:21PM  U.S. FDA okays expanded use of Medivation prostate cancer drug Reuters
05:08PM  Medivation Resumes Trading After Xtandi Receives FDA Approval at Barrons.com
04:39PM  U.S. FDA Approves New Indication for the Use of XTANDI┬« (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire
04:20PM  U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer Marketwired
03:37PM  Medivation Prostate Cancer Drug Secures Expanded FDA Label at TheStreet
Sep-05-14 08:55AM  Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte at TheStreet
Sep-03-14 11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
Aug-25-14 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired +5.04%
06:48AM  Can Medivation (MDVN) Run Higher on Strong Earnings Estimate Revisions? Zacks
Aug-19-14 04:25PM  Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 Zacks
Aug-11-14 11:10AM  Medivation Jumps on Q2 Earnings Beat, Outlook Encourages Zacks
06:36AM  Medivation (MDVN) Jumps: Stock Adds 7.5% in Session Zacks
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seely LynnChief Medical OfficerOct 22Option Exercise10.595,00052,92564,854Oct 23 06:54 PM
Seely LynnChief Medical OfficerOct 22Sale99.035,000495,14259,854Oct 23 06:54 PM
Seely LynnChief Medical OfficerOct 16Option Exercise10.595,00052,92564,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 16Sale93.975,000469,85059,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Option Exercise8.0024,346194,73784,200Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Sale89.1124,3462,169,36359,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerSep 18Option Exercise10.5925,000264,62584,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 18Sale99.8125,0002,495,15859,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Option Exercise8.4630,000253,80089,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Sale97.3630,0002,920,72759,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 09Option Exercise10.5920,000211,70079,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerSep 09Sale94.6020,0001,892,01659,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerAug 27Option Exercise10.5914,300151,36673,322Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 27Sale89.6114,3001,281,42359,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Option Exercise10.595,70060,33564,722Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Sale88.955,700507,03259,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 13Option Exercise8.3920,000167,82579,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 13Sale83.6220,0001,672,45659,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 12Option Exercise9.3912,500117,31371,522Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 12Sale84.0112,5001,050,12559,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Option Exercise9.3913,000122,00572,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Sale82.0613,0001,066,82159,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerJul 22Option Exercise6.747,50050,51366,522Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 22Sale73.967,500554,71059,022Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 02Option Exercise9.3912,000112,62071,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJul 02Sale79.0212,000948,19459,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJun 18Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 18Sale75.007,500562,53059,022Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Sale74.507,500558,76059,022Jun 19 04:35 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 18Option Exercise10.5940,000423,40070,830Feb 19 04:58 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 18Sale82.7940,0003,311,64630,830Feb 19 04:58 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 11Option Exercise10.5940,000423,40070,830Feb 12 05:34 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 11Sale80.8340,0003,233,12130,830Feb 12 05:34 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 05Option Exercise10.5940,000423,40070,830Feb 06 05:24 PM
Machado Clarence PatrickChief Business Officer and CFOFeb 05Sale73.4640,0002,938,57430,830Feb 06 05:24 PM
Machado Clarence PatrickChief Business Officer and CFOJan 28Option Exercise10.5940,000423,40070,830Jan 29 07:33 PM
Machado Clarence PatrickChief Business Officer and CFOJan 28Sale75.4340,0003,017,12230,830Jan 29 07:33 PM
Hung DavidPresident and CEOJan 27Option Exercise5.88150,000882,0001,100,204Jan 28 05:39 PM
Hung DavidPresident and CEOJan 27Sale73.50150,00011,025,357950,204Jan 28 05:39 PM
Machado Clarence PatrickChief Business Officer and CFOJan 21Option Exercise10.5940,000423,40070,830Jan 23 07:24 PM
Machado Clarence PatrickChief Business Officer and CFOJan 21Sale76.2940,0003,051,62730,830Jan 23 07:24 PM
Rhodes Jennifer JGC & Chief Compliance OfficerJan 21Sale76.2814,0001,067,9496,000Jan 23 07:23 PM